Article PDF
Avoid common mistakes on your manuscript.
References
Chandler RE. Serious neurological adverse events after ivermectin-Do they occur beyond the indication of onchocerciasis? Am J Trop Med Hyg. 2018;98:382–88.
Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
Baudou E, Lespine A, Durrieu G, et al. Serious lvermectin toxicity and human ABCB1 nonsense mutations. N Engl J Med. 2020; 383:787–89
Jans DA, Wagstaff KM. The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2? Biochem Biophys Res Commun. 2021;538:163–72.
González Canga A, Sahagún Prieto AM, Diez Liébana MJ, et al. The pharmacokinetics and interactions of ivermectin in humans-A mini-review. AAPS J. 2008;10:42–6.
Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux JP. Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J. 2003;2:S4.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Talwar, N., Tripathi, N. & Chugh, K. Ivermectin Poisoning — Report of Successful Management. Indian Pediatr 58, 893–894 (2021). https://doi.org/10.1007/s13312-021-2316-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-021-2316-1